![]() |
5th Conference on Retroviruses and Opportunistic InfectionsChicago, IL - February 1-5, 1998 |
Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:80 (abstract no. 7)
Henderson LE, Chertova E, Ott D, Hewes SM, Cases-Finet JR, Kane B, Johnson DG, Sowder II RC, Rossio J, Lifson J, Arthur LO
NCI-FCRDC, Frederick, MD.
Retroviral nucleocapsid (NC) proteins contain one or two zinc fingers (ZFs) consisting of a Cys(X)2Cys(X)4His(X)4Cys (CCHC) peptide motif that coordinates Zn(II). Mutational and biochemical analyses have shown that NC ZFs are required for viral replication and are directly involved in multiple stages of viral replication cycle including genomic RNA encapsidation, virus maturation, and the early infection process. We have previously shown that Cys thiols in retroviral NC ZFs are susceptible to chemical attack by a wide variety of chemical compounds which can inactivate whole virus. Many of these compounds are non-toxic and thus have the potential to serve as lead compounds for the development of a new class of therapeutic anti-retrovirals. To continue this exploration we have developed methods to:
These results show that at least one compound has been identified which has an enhanced reactivity with the target NC protein, inactivates whole virus (SIV, HIV-1 and MuLV), react selectively with the whole viral NC protein, is non-toxic, can be taken orally and reduces viral replication in the MuLV/mouse model and in the SIV/monkey model. These results strongly support the suggestion that the reactivity of the NC protein CCHC ZFs can be exploited to develop a new class of anti-retroviral compounds that may find therapeutic applications.
1998-02-01
7
Copyright © 1998 - Foundation for Retrovirology and Human Health (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed from National Library of Medicine.